Business Review 13 REPORTING PERFORMANCE Sales by growth, patent expiry and base products $m and % change 05 10,643 4% 1 2,458 -20% 0,849 27% 23,950 04 10,024 5% 2,976 -26% 8,426 36% 21,426 03 9,102 12% 3,761 -46% 5,986 53% 18,849 Base Patent expiry Losec, Nolvadex, Plendil and Zestril Growth Arimidex, Crestor, Nexium, Seroquel and Symbicort Growth product sales growth Gross margin $m The perfomance data shown in the therapy area reviews on pages 14, 18, 21, 24, 27 and 30 and the geographic and US prescription share trends sales performance in the geographic review on page 31 % of sales are shown in both reported and underlying performance.
Nexium Reported performance takes into account all the factors Sales $m TRx share 05 18,594 77.6% including those which we cannot influence, principally currency exchange rates that have affected the results 4,633 30.3% 04 16,233 75.8% of our business.
Underlying performance shows sales growth at constant exchange rates CER to reflect the volume and price changes of the geographic and therapy 3,883 26.9% 03 14,386 76.3% areas and individual products by excluding the effects of exchange rate movements.
A description of the calculation 3,302 25.3% of this measure is set out in the Financial Review on page 45, together with the reasons for its use.
Symbicort has not been launched in the US.
